AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10597880
Drug: CEE +
RxNorm normalized name: Conjugated Estrogen Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE + MPA (2.5 mg/day)
Trial: 10597880
Drug: CEE +
RxNorm normalized name: Conjugated Estrogen Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE + NG (0.05 mg/day)
Trial: 8565031
Drug: Calcitonin salmon
RxNorm normalized name: Calcitonin Salmon
DrugBank: Salmon calcitonin (DB00017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcitonin salmon nasal spray (200 IU/d)
Trial: 8565031
Drug: Calcitonin salmon
RxNorm normalized name: Calcitonin Salmon
DrugBank: Salmon calcitonin (DB00017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcitonin salmon nasal spray
Trial: 2035326
Drug: Intravenous aminophylline
RxNorm normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous aminophylline (n = 11)
Trial: 2035326
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (n = 11)
Trial: 28485777
Drug: 0.10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.10 mg/kg vecuronium bromide combined with propofol and fentanyl
Trial: 7308554
Drug: Betnovate (betamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betnovate (betamethasone 17‐valerate, 0.1%) cream diluted to 50% in various vehicles
Trial: 7308554
Drug: Other formulations
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other formulations tested
Trial: 30557295
Drug: Standard outpatient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard outpatient physical therapy (PT)
Trial: 28209333
Drug: Green tea
RxNorm normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green tea extract (GTE) supplementation (0.9 g GTE per day for 12 months)
Trial: 24154935
Drug: Linagliptin 5mg
RxNorm normalized name: LINAGLIPTIN 5MG TAB
DrugBank: Linagliptin (DB08882)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Linagliptin 5mg once-daily
Trial: 24154935
Drug: Linagliptin 2.5mg
RxNorm normalized name: LINAGLIPTIN 2.5MG/METFORMIN HCL 500MG TAB,ORAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linagliptin 2.5mg twice-daily
Trial: 21824990
Drug: Aliskiren (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aliskiren (150 mg titrated to 300 mg once daily after 3 months)
Trial: 14676992
Drug: Estradiol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estradiol (50 microg transdermal 17beta‐estradiol)
Trial: 9660986
Drug: Oral cimetidine
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral cimetidine
Trial: 1251156
Drug: Bactrim (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bactrim (2 x 2 tablets or ampoules daily)
Trial: 26589819
Drug: Lisinopril (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril (n = 9,054)
Trial: 24388839
Drug: Trimethoprim-sulfamethoxazole (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim-sulfamethoxazole (800 mg/160 mg) twice daily for 45 days, followed by tablet every 2 days
Trial: 24388839
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet every 2 days
Trial: 11701687
Drug: Alfacalcidol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfacalcidol (1 microg daily)
Trial: 20406615
Drug: Cumulative glucocorticoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cumulative glucocorticoid dose
Trial: 10333345
Drug: Glucose 20%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose 20% infusion at 0.3, 1.0, and 3.0 ml/min for 5 min each
Trial: 10333345
Drug: Saline 0.9%
RxNorm normalized name: CVS Saline 0.9% Nasal Mist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline 0.9% infusion
Trial: 10333345
Drug: Glucose 20%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose 20% infusion during local hyperinsulinaemia (insulin 0.05 mU/kg/min)
Trial: 10333345
Drug: Saline 0.9%
RxNorm normalized name: CVS Saline 0.9% Nasal Mist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline 0.9% infusion during local hyperinsulinaemia
Trial: 8983282
Drug: Cisplatin dose
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin dose adjustment to reach a target plasma concentration of total platinum (TP) of 2000 mu/l
Trial: 8983282
Drug: Cisplatin without
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin without dose adjustment
Trial: 8983282
Drug: Cisplatin dose
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin dose adjustment
Trial: 1834864
Drug: Goserelin acetate
RxNorm normalized name: Goserelin Acetate
DrugBank: Goserelin (DB00014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Goserelin acetate plus flutamide (250 mg 3 times daily)
Trial: 30580081
Drug: L-theanine (450–900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-theanine (450–900 mg)
Trial: 26791438
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment twice a week for 2 months
Trial: 25247967
Drug: Thin-slice low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Thin-slice low-dose CT measurements in airways with a luminal diameter of 5 to 10 mm
Trial: 25247967
Drug: Thin-slice low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Thin-slice low-dose CT measurements in airways with a luminal diameter of 10 mm or greater
Trial: 18573585
Drug: omega-3 PUFAs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: omega-3 PUFAs 1.8 g/day
Trial: 10863061
Drug: No further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No further treatment (S alone)
Trial: 9089857
Drug: Patient-controlled analgesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled analgesia with a constant subarachnoid infusion of 0.6 mg/h of bupivacaine and self-administration of 0.6 mg every 30 minutes
Trial: 9089857
Drug: Bolus administration
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus administration of 3.75 mg of plain bupivacaine on request
Trial: 9089857
Drug: Patient-controlled analgesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled analgesia with a constant subarachnoid infusion of 0.6 mg/h of bupivacaine
Trial: 9089857
Drug: Patient-controlled analgesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled analgesia with a continuous background infusion via microspinal catheters
Trial: 9089857
Drug: Bolus administration
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus administration of bupivacaine
Trial: 3510540
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with sympathomimetics and methylxanthines
Trial: 26103979
Drug: Progressive spacing
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Progressive spacing of TNF-blocker injections (S-arm)
Trial: 26103979
Drug: Maintenance of
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance of TNF-blocker injections (M-arm)
Trial: 25793955
Drug: Daily ingestion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily ingestion of a mixture of probiotics in addition to brushing teeth and using fluoridated toothpaste.
Trial: 23232966
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of cefazolin intramuscularly (reference group)
Trial: 23232966
Drug: 10 mL
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL of isotonic sodium chloride solution (study group)
Trial: 18236391
Drug: FK (trough,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FK (trough, 6‐10 ng/mL)
Trial: 18236391
Drug: CsA (C2,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CsA (C2, 600‐1200 ng/mL)
Trial: 16774104
Drug: Other clobetasol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other clobetasol propionate preparations (solution, foam, cream, lotion, shampoo, emollient)
Trial: 14660202
Drug: Fitness training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fitness training added to treatment
Trial: 14660202
Drug: Multifaceted treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multifaceted treatment (without fitness training)
Trial: 10741688
Drug: GH therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH therapy (0.25 IU x kg per week)
Trial: 8694313
Drug: Intravenous ondansetron,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ondansetron, 0.15 mg/kg
Trial: 1552202
Drug: Live attenuated
RxNorm normalized name: mumps, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live attenuated trivalent cold-recombinant influenza vaccine (10^5 TCID50 of each strain)
Trial: 1552202
Drug: Live attenuated
RxNorm normalized name: mumps, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live attenuated trivalent cold-recombinant influenza vaccine
Trial: 31430268
Drug: RPh201 (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RPh201 (20 mg) administered subcutaneously twice weekly
Trial: 31430268
Drug: Placebo (cottonseed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (cottonseed oil vehicle) administered subcutaneously twice weekly
Trial: 28419650
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (solifenacin 5 mg/mirabegron 25 mg, increasing to 50 mg after week 4)
Trial: 25304838
Drug: Butylscopolamine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butylscopolamine (20 mg intravenously immediately before the end of the operation)
Trial: 25304838
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no medication for prevention of CRBD)
Trial: 23720276
Drug: Intramyocardial injection
RxNorm normalized name: ALCOHOL 80 mL in 100 mL INTRAEPICARDIAL LIQUID [80% Alcohol Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramyocardial injection of autologous BM-MNC
Trial: 23720276
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of intramyocardial and intracoronary injection of autologous BM-MNC
Trial: 17682094
Drug: Ceftaroline (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftaroline (600 mg every 12 h)
Trial: 17682094
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (i.v. vancomycin 1 g every 12 h with or without adjunctive i.v. aztreonam 1 g every 8 h)
Trial: 9421387
Drug: Troglitazone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troglitazone (200 mg once daily)
Trial: 7652582
Drug: INF-alpha therapy
RxNorm normalized name: r-INF-alpha
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: INF-alpha therapy
Trial: 7652582
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of INF-alpha therapy with other chemotherapeutic agents and/or biologicals
Trial: 2673315
Drug: Felodipine (chronic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine (chronic oral treatment for 8 weeks)
Trial: 2673315
Drug: Felodipine (acute
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine (acute intravenous administration)
Trial: 2673315
Drug: Felodipine (chronic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine (chronic oral treatment)
Trial: 790413
Drug: Oral fluphenazine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral fluphenazine (5-20 mg)
Trial: 790413
Drug: Depot fluphenazine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Depot fluphenazine (25 mg/q 3 weeks)
Trial: 790413
Drug: Both oral
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both oral and depot fluphenazine
Trial: 790413
Drug: Oral and
RxNorm normalized name: Tridate, oral and rectal kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral and depot fluphenazine
Trial: 790413
Drug: Dosage equivalence
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage equivalence
Trial: 26235006
Drug: Adverse neurological
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adverse neurological event(s) during therapy
Trial: 17965485
Drug: Aspirin plus
RxNorm normalized name: Aspirin Plus Antacid Extra Strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin plus clopidogrel or ticlopidine (Group I, n=28)
Trial: 17965485
Drug: Aspirin plus
RxNorm normalized name: Aspirin Plus Antacid Extra Strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin plus clopidogrel or ticlopidine plus cilostazol (Group II, n=31)
Trial: 11193233
Drug: Megestrol acetate
RxNorm normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Megestrol acetate (MA) oral suspension of 800 mg/d for 12 weeks
Trial: 9777138
Drug: Hirulog and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hirulog and aspirin before streptokinase
Trial: 9777138
Drug: Heparin with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin with streptokinase
Trial: 8172139
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no treatment or placebo)
Trial: 30522806
Drug: Intra-articular injection
RxNorm normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injection of 0.5–0.6 × 10^8 allogenic placenta-derived MSCs
Trial: 26353784
Drug: Truce program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Truce program (7-week acceptance and commitment therapy)
Trial: 19142978
Drug: Prelox (combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prelox (combination of l-arginine aspartate and Pycnogenol)
Trial: 17519075
Drug: IL‐12/23 mAb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL‐12/23 mAb (0.27, 0.675, 1.35, and 2.7 mg/kg)
Trial: 10606880
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (UFH), 250 U/kg twice daily
Trial: 10606880
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (UFH), 300 U/kg once daily
Trial: 10606880
Drug: Dalteparin, 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalteparin, 200 U/kg once daily
Trial: 10606880
Drug: Enoxaparin, 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin, 1.5 mg/kg once daily
Trial: 7750288
Drug: High doses
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High doses of vitamin C (gram quantities)
Trial: 7750288
Drug: Combination oral
RxNorm normalized name: PROBIOTIC COMBINATION ORAL CAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination oral contraceptive alone
Trial: 2292897
Drug: Teolin 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teolin 300 tablets (TT)
Trial: 2292897
Drug: Teotard 350
RxNorm normalized name: Ketotard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teotard 350 capsules (TC)
Trial: 7016451
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg tolmetin sodium daily
Trial: 1092728
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg naproxen daily
Trial: 25517106
Drug: 7.5% sucrose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5% sucrose drink containing 6 g of l-citrulline
Trial: 25517106
Drug: 710 mL
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 710 mL of watermelon juice (1.0 g citrulline)
Trial: 21679291
Drug: Insulin glulisine
RxNorm normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Insulin glulisine (single pre-prandial dose)
Trial: 21679291
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine (basal-only control)
Trial: 15012046
Drug: Exercise during
RxNorm normalized name: Pro-C-Dure 6 Kit KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise during dialysis (cycling ergometer sessions, twice weekly for 12 sessions)
Trial: 21813912
Drug: NO(2) Platinum
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NO(2) Platinum (12 g/day)
Trial: 19103500
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (1 g bolus before skin incision and 400 mg/h during surgery)
Trial: 9265991
Drug: Cetirizine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine treatment for allergic cough
Trial: 3404638
Drug: Adjusted-dose heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjusted-dose heparin (mean 13,200 +/- 2200 U per dose, APTT 1 1/2 times control)
Trial: 3404638
Drug: Fixed-dose heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose heparin (5000 U subcutaneously twice daily)
Trial: 30346496
Drug: Standard PIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard PIL (e.g., 'Common, 1 in 10 people will be affected')
Trial: 30346496
Drug: Positively framed
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positively framed PIL (e.g., 'Uncommon, 90% of people will not be affected')
Trial: 12760589
Drug: Sildenafil 25
RxNorm normalized name: sildenafil 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil 25 mg 8 hourly for two weeks
Trial: 10857950
Drug: Antihypertensive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive treatment (AHT) with enalapril or metoprolol
Trial: 10857950
Drug: No antihypertensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antihypertensive treatment (AHT)
Trial: 2053757
Drug: Intravenous injection
RxNorm normalized name: Meta Trace FDG, intravenous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of 1 or 2 g of oxacillin before surgery, followed by four days of oral oxacillin (3 g per day).
Trial: 2053757
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group without the use of prophylactic antibiotics.
Trial: 7049344
Drug: Intrathecal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal therapy with methotrexate, hydrocortisone, and cytosine arabinoside plus cranial radiation (2400 rad over 2 1/2 weeks)
Trial: 7049344
Drug: Intrathecal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal therapy with methotrexate, hydrocortisone, and cytosine arabinoside without cranial radiation
Trial: 26469916
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy without collection of wound exudate
Trial: 21207054
Drug: CRE +
RxNorm normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CRE + CAF (0.3 g kg(‐1) day(‐1) of creatine for 5 days and followed by 6 mg kg(‐1) of caffeine)
Trial: 21207054
Drug: CRE +
RxNorm normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CRE + PLA (0.3 g kg(‐1) day(‐1) of creatine for 5 days then followed by 6 mg kg(‐1) of placebo)
Trial: 15467309
Drug: Desmopressin (DDAVP)
RxNorm normalized name: desmopressin Injection [DDAVP]
DrugBank: Desmopressin (DB00035)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Desmopressin (DDAVP) at a dose of 2 microg/kg intranasally
Trial: 11208820
Drug: Preoperative chemoradiation
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative chemoradiation with cisplatin, fluorouracil, and vinblastine; cisplatin 20 mg/m2/d on days 1-5 and 17-21, fluorouracil 300 mg/m2/d on days 1-21, vinblastine 1 mg/m2/d on days 1-4 and 17-20, radiotherapy 1.5-Gy fractions twice daily for 21 days to a total dose of 45 Gy.
Trial: 3275909
Drug: ethinyl estradiol
RxNorm normalized name: Ethinyl Estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ethinyl estradiol 35 micrograms plus ethynodiol diacetate 1 mg
Trial: 3275909
Drug: ethinyl estradiol
RxNorm normalized name: Ethinyl Estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ethinyl estradiol 30 micrograms plus levonorgestrel 0.15 mg